MCID: ACT098
MIFTS: 51

Acute Erythroid Leukemia

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Acute Erythroid Leukemia

MalaCards integrated aliases for Acute Erythroid Leukemia:

Name: Acute Erythroid Leukemia 39 54
Acute Erythroleukemia 54 17 74
Erythroleukemia 54 56 17
Acute Myeloid Leukemia, M6 Type 30 6
Acute Myeloid Leukemia Fab-M6 54 74
Acute Erythroleukemia - M6a Subtype 74
Acute Erythroleukemia - M6b Subtype 74
Acute Erythroleukemia M6a Subtype 54
Acute Erythroleukemia M6b Subtype 54
Acute Erythroblastic Leukemia 74
Acute Myeloid Leukemia M6 54
Di Guglielmo's Syndrome 54
Di Guglielmo Syndrome 54
Aml M6 54
Aml-M6 54

Classifications:



Summaries for Acute Erythroid Leukemia

MalaCards based summary : Acute Erythroid Leukemia, also known as acute erythroleukemia, is related to leukemia and megakaryocytic leukemia. An important gene associated with Acute Erythroid Leukemia is ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3), and among its related pathways/superpathways are Development EGFR signaling pathway and NF-kappaB Signaling. The drugs Mesna and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are cellular and embryo

Wikipedia : 77 Acute erythroid leukemia is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the... more...

Related Diseases for Acute Erythroid Leukemia

Diseases related to Acute Erythroid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 leukemia 30.0 CEBPA ERBB3 JAK2 TP53
2 megakaryocytic leukemia 29.4 JAK2 TP53
3 myelodysplastic syndrome 29.2 CEBPA GATA2 JAK2 TP53
4 myeloid leukemia 28.5 CEBPA GATA2 JAK2 PICALM TP53
5 erythroleukemia, familial 11.4
6 anemia, congenital dyserythropoietic, type iii 11.3
7 folate malabsorption, hereditary 11.2
8 pernicious anemia 10.3
9 polycythemia 10.2
10 paroxysmal nocturnal hemoglobinuria 10.1
11 sarcoma 10.1
12 teratocarcinoma 10.1
13 embryonal carcinoma 10.1
14 hemoglobinuria 10.1
15 hypoxia 10.1
16 macrocytic anemia 10.0
17 hemolytic anemia 10.0
18 thalassemia 10.0
19 lymphoma 10.0
20 core binding factor acute myeloid leukemia 10.0 CEBPA JAK2
21 leukemia, chronic lymphocytic 2 9.9
22 leukemia, chronic lymphocytic 9.9
23 myeloma, multiple 9.9
24 hemophagocytic lymphohistiocytosis, familial, 2 9.9
25 acute leukemia 9.9
26 lymphocytic leukemia 9.9
27 vasculitis 9.9
28 leukemia, b-cell, chronic 9.9
29 myelodysplastic syndrome with excess blasts 9.9
30 hepatocellular carcinoma 9.9
31 rheumatoid arthritis 9.9
32 myelofibrosis 9.9
33 headache associated with sexual activity 9.9
34 ovarian cancer 1 9.9
35 arthritis 9.9
36 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 9.9
37 congenital dyserythropoietic anemia 9.9
38 hypersensitivity reaction type iv disease 9.9
39 plasmacytoma 9.9
40 refractory anemia 9.9
41 atypical chronic myeloid leukemia 9.9 JAK2 PCM1
42 burkitt lymphoma 9.8
43 fetal hemoglobin quantitative trait locus 1 9.8
44 pelger-huet anomaly 9.8
45 pheochromocytoma 9.8
46 retinoblastoma 9.8
47 polycythemia vera 9.8
48 pyruvate kinase deficiency of red cells 9.8
49 reticulum cell sarcoma 9.8
50 werner syndrome 9.8

Graphical network of the top 20 diseases related to Acute Erythroid Leukemia:



Diseases related to Acute Erythroid Leukemia

Symptoms & Phenotypes for Acute Erythroid Leukemia

MGI Mouse Phenotypes related to Acute Erythroid Leukemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 CEBPA ERBB3 GATA2 JAK2 PICALM TP53
2 embryo MP:0005380 9.72 ERBB3 GATA2 JAK2 PICALM TP53
3 integument MP:0010771 9.65 CEBPA ERBB3 JAK2 PICALM TP53
4 liver/biliary system MP:0005370 9.55 CEBPA GATA2 JAK2 PICALM TP53
5 neoplasm MP:0002006 9.26 CEBPA ERBB3 JAK2 TP53
6 normal MP:0002873 9.1 CEBPA ERBB3 FHL2 GATA2 JAK2 TP53

Drugs & Therapeutics for Acute Erythroid Leukemia

Drugs for Acute Erythroid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 3 3375-50-6 598
2
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
5
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
7
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
8
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
9
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
10
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
11
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
12
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
13
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
14
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
16
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
18
Cladribine Approved, Investigational Phase 3,Phase 2,Phase 1 4291-63-8 20279
19
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Prednisone Approved, Vet_approved Phase 3,Phase 1 53-03-2 5865
21
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
22
Mercaptopurine Approved Phase 3 50-44-2 667490
23
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
24
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
25
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
26
Carmustine Approved, Investigational Phase 3 154-93-8 2578
27
Hydroxyurea Approved Phase 3 127-07-1 3657
28
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
29
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
30
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
31
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 460612 4053
32
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
33
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
34
Histamine Approved, Investigational Phase 3 51-45-6 774
35
midostaurin Approved, Investigational Phase 3 120685-11-2 9829523 104937
36
Cyproheptadine Approved Phase 3 129-03-3 2913
37
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 444795 5538
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
39 Lintuzumab Investigational Phase 3,Phase 2 166089-32-3
40
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
41 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
42 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Etoposide phosphate Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
2 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
3 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
4 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
6 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Completed NCT00136084 Phase 3 Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone;Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
9 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
10 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
12 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
13 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
14 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
15 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
16 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
17 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
18 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
19 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
20 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
21 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
22 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
23 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
24 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
25 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
26 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
27 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
28 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
31 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
32 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
33 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
34 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
35 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
36 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
37 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
38 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
39 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
40 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
41 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT02019069 Phase 2 liposomal cytarabine-daunorubicin CPX-351
42 Vorinostat in Treating Patients With Acute Myeloid Leukemia Completed NCT00305773 Phase 2 vorinostat;vorinostat
43 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
44 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
45 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
46 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
47 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
48 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
49 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
50 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride

Search NIH Clinical Center for Acute Erythroid Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Erythroid Leukemia cell therapies at LifeMap Discovery.

Genetic Tests for Acute Erythroid Leukemia

Genetic tests related to Acute Erythroid Leukemia:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia, M6 Type 30 ERBB3

Anatomical Context for Acute Erythroid Leukemia

MalaCards organs/tissues related to Acute Erythroid Leukemia:

42
Myeloid, Bone, Bone Marrow, B Cells, Breast, Spleen, Brain

Publications for Acute Erythroid Leukemia

Articles related to Acute Erythroid Leukemia:

(show top 50) (show all 75)
# Title Authors Year
1
Genomic subtyping and therapeutic targeting of acute erythroleukemia. ( 30926971 )
2019
2
Genomic Analysis Provides Insights into Acute Erythroleukemia. ( 30979704 )
2019
3
The anticancer effects of pharmacological inhibition of autophagy in acute erythroid leukemia cells. ( 29994802 )
2018
4
Knockdown of Long Noncoding RNA Plasmacytoma Variant Translocation 1 with Antisense Locked Nucleic Acid GapmeRs Exerts Tumor-Suppressive Functions in Human Acute Erythroleukemia Cells Through Downregulation of C-MYC Expression. ( 30141968 )
2018
5
Antiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells. ( 30073438 )
2018
6
Induction of apoptosis and necrosis in human acute erythroleukemia cells by inhibition of long non-coding RNA PVT1. ( 30046623 )
2018
7
Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia. ( 27389056 )
2017
8
An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification. ( 28793875 )
2017
9
Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. ( 28841205 )
2017
10
Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. ( 28886412 )
2017
11
Clinical Characteristics and Prognosis of 167 Cases of Acute Erythroleukemia. ( 28194057 )
2017
12
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. ( 28420120 )
2017
13
Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. ( 26202927 )
2016
14
microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. ( 27086927 )
2016
15
Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. ( 27244257 )
2016
16
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. ( 27443511 )
2016
17
The disappearance of acute erythroid leukemia: An act of legerdemain at the World Health Organization. ( 27667167 )
2016
18
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. ( 26293512 )
2016
19
Kefir induces apoptosis and inhibits cell proliferation in human acute erythroleukemia. ( 26708130 )
2016
20
A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. ( 27416908 )
2016
21
Extreme dyserythropoiesis in the setting of acute erythroid leukemia. ( 26605391 )
2015
22
A case of acute erythroleukemia with concurrence of BCR-ABL and FLT3-TKD (D835E) mutation. ( 25547655 )
2015
23
Erythropoietin-induced acute erythroid leukemia-like picture: a potential pitfall. ( 24239851 )
2014
24
Differential diagnoses of macrocytic anemia, reticulocytosis and low serum haptoglobin in patients with myelodysplastic syndromes/acute leukemia: comment on "two cases of acute erythroid leukemia presenting with marked macrocytic anemia, reticulocytosis and hemolysis". ( 24390535 )
2014
25
Acute erythroid leukemia in a patient with chronic lymphocytic leukemia. ( 25536628 )
2014
26
High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24). ( 23032695 )
2013
27
Large vessel vasculitis developed early after allogeneic bone marrow transplant for acute erythroid leukemia. ( 23517561 )
2013
28
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. ( 23648669 )
2013
29
Fusion of ZMYND8 and RELA genes in acute erythroid leukemia. ( 23667654 )
2013
30
Two cases of acute erythroid leukemia presenting with marked macrocytic anemia, reticulocytosis and hemolysis. ( 23812200 )
2013
31
Unbalanced 11;18 translocation in an acute erythroid leukemia after radioactive iodine therapy. ( 23871646 )
2013
32
Treatment of acute erythroleukemia with Azacitidine: A case series. ( 24371777 )
2013
33
Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification. ( 21780998 )
2012
34
The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics. ( 21996560 )
2012
35
Block of red blood cell maturation in acute erythroid leukemia. ( 23115799 )
2012
36
Florid erythroid dysplasia mimicking congenital dyserythropoietic anemia during the preleukemic phase of acute erythroleukemia. ( 22292463 )
2012
37
Downregulation of nucleoporin 88 and 214 induced by oridonin may protect OCIM2 acute erythroleukemia cells from apoptosis through regulation of nucleocytoplasmic transport of NF-κB. ( 22824908 )
2012
38
Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. ( 21264917 )
2011
39
Translocation t(1;16)(p31;q24) rearranging CBFA2T3 is specific for acute erythroid leukemia. ( 21606959 )
2011
40
Acute erythroid leukemia with multilineage dysplasia in a cat. ( 21731091 )
2011
41
S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13). ( 22147971 )
2011
42
FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia. ( 22829078 )
2011
43
A case of acute erythroleukemia evolved from myelodysplastic syndrome with acquisition of Ph chromosome and review of the literature. ( 21329980 )
2011
44
Childhood acute erythroleukemia diagnosis by flow cytometry. ( 21393910 )
2011
45
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. ( 20040759 )
2010
46
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. ( 20473273 )
2010
47
Acute erythroid leukemia. ( 20807044 )
2010
48
Acute erythroleukemia: diagnosis and management. ( 21091147 )
2010
49
Acute erythroid leukemia (AML-M6) - Is it rare? ( 27265109 )
2009
50
Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. ( 19713696 )
2009

Variations for Acute Erythroid Leukemia

ClinVar genetic disease variations for Acute Erythroid Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ERBB3 NM_001982.3(ERBB3): c.4009G> A (p.Ala1337Thr) single nucleotide variant Likely pathogenic rs755855285 GRCh38 Chromosome 12, 56102035: 56102035
2 ERBB3 NM_001982.3(ERBB3): c.4009G> A (p.Ala1337Thr) single nucleotide variant Likely pathogenic rs755855285 GRCh37 Chromosome 12, 56495819: 56495819

Expression for Acute Erythroid Leukemia

Search GEO for disease gene expression data for Acute Erythroid Leukemia.

Pathways for Acute Erythroid Leukemia

GO Terms for Acute Erythroid Leukemia

Biological processes related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.62 CEBPA FHL2 GATA2 TP53
2 cell differentiation GO:0030154 9.58 GATA2 JAK2 TP53
3 cytokine-mediated signaling pathway GO:0019221 9.54 CEBPA JAK2 TP53
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 ERBB3 JAK2
5 cell maturation GO:0048469 9.26 CEBPA GATA2
6 response to antibiotic GO:0046677 9.16 JAK2 TP53
7 embryonic placenta development GO:0001892 8.96 CEBPA GATA2
8 positive regulation of transcription, DNA-templated GO:0045893 8.92 CEBPA FHL2 PICALM TP53

Molecular functions related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.35 ERBB3 FHL2 JAK2 PCM1 TP53
2 transcription factor binding GO:0008134 8.92 CEBPA FHL2 GATA2 TP53

Sources for Acute Erythroid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....